Nuvalent Inc - Ordinary Shares - Class A Stock

$75.01

1.35% today

Nasdaq, Aug 18, 10:00 pm CET

ISIN

US6707031075

Symbol

NUVL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Nuvalent Inc - Ordinary Shares - Class A Stock price

$76.04

+57.29 305.55% 5Y

Nasdaq, Closing price Fri, Aug 15 2025

-0.76 0.99%

ISIN

US6707031075

Symbol

NUVL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$5.4b

Enterprise Value

$4.3b

Net debt

positive

Cash

$1.1b

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

5.4

Financial Health

Equity Ratio

93.7%

Return on Equity

-24.4%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | $-379.0m

EBIT

$-362.0m | $-399.4m

Net Income

$-343.3m | -

Free Cash Flow

$-239.2m

EPS

$-4.8

FCF per Share

Short interest

17.3%

Employees

200

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

Nuvalent Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

18x Buy

95%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a Nuvalent Inc - Ordinary Shares - Class A forecast:

Buy

95%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Nuvalent Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	77 77	54% 54% -
- Research and Development Expense	285 285	86% 86% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-362 -362	78% 78% -
Net Profit	-343 -343	98% 98% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Nuvalent Inc - Ordinary Shares - Class A Stock News

Neutral

PRNewsWire

●

5 days ago

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass. , Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-sm...

Neutral

The Motley Fool

●

11 days ago

Nuvalent (NUVL) Q2 R&D Up 65%

Nuvalent (NUVL -1.77%), a clinical-stage biotechnology company developing therapies for cancers driven by kinase mutations, released its second quarter 2025 earnings results on August 7, 2025. There was no product revenue, consistent with expectations for a pre-commercial biotech.

Neutral

PRNewsWire

●

11 days ago

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Prel...

More Nuvalent Inc - Ordinary Shares - Class A News

Company Profile

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Head office	United States
CEO	James Porter
Employees	200
Founded	2017
Website	www.nuvalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now